-+ 0.00%
-+ 0.00%
-+ 0.00%

Pfizer And BioNTech Announced Topline Results From An Ongoing Phase 3 Trial Cohort Evaluating 30-µg Dose Of LP.8.1-adapted Monovalent Comirnaty 2025-2026 Formula, Demonstrating Robust Immune Response In Older Patients

Benzinga·09/08/2025 10:48:37
Listen to the news
  • Phase 3 clinical trial cohort of adults 65+ and 18-64 with at least one underlying risk condition shows at least a 4-fold increase in LP.8.1-neutralizing antibody titers after receiving the LP.8.1-adapted COVID-19 vaccine 2025-2026 Formula
  • First LP.8.1 sublineage clinical findings reinforce pre-clinical data supporting recent FDA approval of 2025-2026 Formula of Pfizer-BioNTech COVID-19 Vaccine
  • Companies have submitted these data to the FDA